As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53
Fiscal 2026 outlook maintained
DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the third quarter was 8%.
"We are pleased with our performance in the third quarter," said Dan Carestio, President and CEO of STERIS. "Our performance continues to benefit from strong execution by our commercial teams and our diversified portfolio. High single digit revenue growth combined with cost discipline is allowing us to deliver meaningful earnings per share growth despite increased tariff headwinds."
Total Company Third Quarter Results from Continuing OperationsAs reported, net income from continuing operations for the third quarter was $192.9 million or $1.96 per diluted share, compared with $173.6 million or $1.75 per diluted share in the third quarter of fiscal 2025. Adjusted net income for the third quarter of fiscal 2026 was $249.4 million or $2.53 per diluted share, compared with the previous year's third quarter of $229.1 million or $2.32 per diluted share.
Third Quarter Segment Results from Continuing OperationsHealthcare revenue as reported grew 9% in the third quarter to $1.1 billion compared with $976.0 million in the third quarter of fiscal 2025. This performance reflected 11% improvement in service revenue, 8% growth in consumable revenue and 7% growth in capital equipment revenue. Constant currency organic revenue growth was 8% compared to last year's third quarter. Healthcare operating income was $258.1 million compared with $246.9 million in last year's third quarter. The increase in operating income was primarily due to improved volume, price, productivity and the benefit of prior restructuring efforts, which were partially offset by tariff costs and inflation.
Fiscal 2026 third quarter revenue for Applied Sterilization Technologies (AST) increased 11% as reported to $286.6 million compared with $258.1 million in the same period last year. This performance reflected 9% growth in service revenue and a 103% growth in capital equipment revenue. Constant currency organic revenue growth was 8% compared to last year's third quarter. Segment operating income was $129.2 million in the third quarter of fiscal 2026, compared with operating income of $115.8 million in the same period last year. The operating income increase compared with the prior year primarily reflects improved price and volume, which were partially offset by continued headwinds in labor and energy costs and unfavorable mix.
Life Sciences third quarter revenue as reported increased 7% to $145.8 million compared with $136.4 million in the third quarter of fiscal 2025. This performance reflected 11% growth in consumable revenue, 7% growth in capital equipment revenue and flat service revenue. Constant currency organic revenue increased 5% compared to last year's third quarter. Operating income increased to $61.8 million in the third quarter of fiscal 2026 compared with $58.1 million in the prior year's third quarter. The operating income increase compared with the prior year primarily reflects improved volume and price, which were partially offset by inflation and tariff costs.
Cash Flow Net cash provided by operations for the first nine months of fiscal 2026 was $1.0 billion, compared with $887.3 million in the first nine months of fiscal 2025. Free cash flow for the first nine months of fiscal 2026 was $737.6 million compared with $588.1 million in the prior year period. The increase in free cash flow during the period was driven primarily by the growth in earnings and lower capital spending.
Fiscal 2026 Outlook ...
